We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Gene Expression Test Effectively Predicts Prostate Cancer Recurrence

By LabMedica International staff writers
Posted on 08 Apr 2010
A new gene expression test is designed to offer urologists an accurate and objective way of determining an individual's recurrence risk, beyond current clinical assessment techniques. More...


Myriad Genetics, Inc. (Salt Lake City, UT, USA) reported data that provides further clinical validation supporting its newest molecular diagnostic product, Prolaris, was presented in March 2010 at the 2010 Genitourinary Cancers Symposium in San Francisco (CA, USA). The abstract of the presentation entitled, "Cell Cycle Genes Predict Recurrence After Radical Prostatectomy,” by Gregory P. Swanson, M.D., from the University of Texas Health Science Center San Antonio (USA), and colleagues.

The study examined a well-described cohort of patients for which 10-year follow-up data were available following prostatectomy surgery. The study was carried out by Dr. Swanson and colleagues at the Scott and White Clinic (Temple, TX, USA) and demonstrated that the Prolaris molecular diagnostic test is a significant predictor of prostate cancer recurrence in training (p = 0.01) and validation cohorts (p = 0.00000006).

In patients with Gleason scores (the most widespread method of prostate cancer tissue grading) below 7, prostate-specific antigen (PSA) levels (protein produced by cells of the prostate gland) of less than 30 ng/mL and with disease confined to the prostate, the Prolaris test accurately identified those patients who had a low risk of disease recurrence with 95% certainty. In contrast, patients with a high-risk signature had a recurrence risk more than four-fold higher than those with a low-risk signature had. In the validation cohort, the test was also prognostic in patients with Gleason scores above 6, PSA levels of greater than 30 ng/mL and with evidence of disease outside the prostate (p = 0.0026).

"These exciting scientific findings provide further support of our new Prolaris molecular diagnostic test and should have significant clinical impact for prostate cancer patients and their physicians,” commented Jerry Lanchbury, Ph.D., chief science officer at Myriad Genetics. "We believe that the Prolaris diagnostic has the potential to transform the care of prostate cancer patients, and that future studies that focus on patients who have not yet undergone surgery will further extend the test's potential clinical utility.”

In the United States, approximately 80,000 men undergo a radical prostatectomy (removal of the prostate gland and some surrounding tissue) each year. Approximately 35% of those men will eventually have a biochemical recurrence indicating the return of their cancer.

Using the test, patients at higher risk of recurrence are candidates for more intensive screening and therapeutic strategies given the aggressiveness of their cancers. Patients at lower risk of recurrence are good candidates for "watchful waiting.”

Prolaris consists of a panel of 46 genes, most of which are involved in cell cycle progression. The test examines standard prostate tumor material available to pathologists to estimate quantitatively the risk of cancer recurrence in patients who have undergone a radical prostatectomy. For the first time, Prolaris provides clinicians with a direct molecular measure of a prostate tumor's capacity to divide and grow by examining genes that drive tumor growth at the molecular level. In the United States alone, 80,000 prostate cancer patients may benefit from the Prolaris risk recurrence assessment each year.

Myriad Genetics is a molecular diagnostic company focused on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine products.

Related Links:

Myriad Genetics
University of Texas Health Science Center San Antonio
Scott and White Clinic



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Candida Glabrata Test
ELIchrom Glabrata
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.